SFES SAFEGUARD SCIENTIFICS INC
Investors, NEC · OTC · SEC CIK 86115 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (2023Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY31.1%
TTM EPS YoY29.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-36.0%
ROA-32.5%
ROIC (approx.)-28.3%
Asset turnover—
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.34x
Accruals ratio-21.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 | FY2019*2019-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| SG&A expense | $5.68M | $4.78M | $7.15M | $9.47M | $9.98M |
| Operating income | -$5.68M | -$4.78M | -$7.15M | -$9.47M | -$9.98M |
| Interest expense | — | — | — | $0 | $14.02M |
| Pretax income | -$9.83M | -$14.26M | $27.00M | -$37.62M | $54.56M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$9.83M | -$14.26M | $27.00M | -$37.62M | $54.56M |
| EBITDA | — | — | — | -$9.47M | -$9.17M |
| EPS (basic) | -0.61 | -0.87 | 1.36 | -1.81 | 2.64 |
| EPS (diluted) | -0.61 | -0.87 | 1.36 | -1.81 | 2.64 |
| Weighted avg. shares (diluted) | 16.22M | 16.34M | 19.83M | 20.75M | 20.64M |
| Balance sheet | |||||
| Cash & equivalents | $9.50M | $13.33M | $24.76M | $15.60M | $25.05M |
| Short-term investments | $0 | $5.96M | $0 | — | — |
| Current assets | $9.91M | $21.42M | $30.28M | $16.06M | $26.35M |
| PP&E, net | — | — | — | $1.79M | $2.10M |
| Total assets | $22.84M | $37.69M | $54.03M | $69.03M | $107.58M |
| Current liabilities | $2.05M | $1.82M | $1.73M | $3.47M | $2.43M |
| Total liabilities | $2.86M | $3.12M | $3.46M | $6.16M | $5.84M |
| Shareholders' equity | $19.98M | $34.58M | $50.57M | $62.88M | $101.74M |
| Shares outstanding | — | 21.57M | 21.57M | 21.57M | — |
| Cash flow statement | |||||
| Operating cash flow | -$3.31M | -$3.26M | -$8.15M | -$8.14M | -$19.97M |
| Investing cash flow | $5.72M | -$4.66M | $58.11M | -$1.27M | $126.30M |
| Financing cash flow | -$6.25M | -$3.49M | -$40.80M | -$40,000 | -$89.48M |
| Depreciation & amortization | — | — | — | $0 | $808,000 |
| Stock-based compensation | $1.12M | $1.45M | $1.78M | $965,000 | $1.24M |
| Dividends paid | $5.82M | $0 | — | $0 | $20.68M |
| Share buybacks | $75,000 | $2.94M | $40.66M | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· Financial companies (banks, insurers, …) usually do not report gross profit or operating income; bank revenue is net revenue (net interest income + noninterest income), smaller than "gross interest income + noninterest income".
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.